The two major T cell immune checkpoint molecules targeted by immunotherapy in NSCLC are cytotoxic T lymphocyte antigen 4 (CTLA-4) and PD-(L)1. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.